POTTERS BAR, ENGLAND, AND SANDTON, JOHANNESBURG -- 14 APRIL 2015 -- In commemoration of World Allergy Week, 13 – 19 April 2015, Mylan N.V., a leading global pharmaceutical company, is working to increase awareness of, and preparedness for, life-threatening allergic reactions, or anaphylaxis.
Anaphylaxis is unpredictable and rapid in onset and occurs when someone comes into contact with an allergic trigger. Food is generally the most common cause. Common food triggers include nuts, shellfish, dairy products, eggs, and sesame seeds. Wasp or bee stings, as well as exercise and certain medications, can also cause anaphylaxis. In about 20% of cases, no trigger is identified.
Globally, between 220 million and 250 million people may suffer from a food allergy and are therefore at risk for anaphylaxis. Although data on anaphylaxis incidence and prevalence is limited, particularly in South Africa, global estimates indicate that food allergies are increasing in both developed and developing countries, especially in children, and that the severity and complexity of food allergies is also increasing.
“Life-threatening allergies are an important and growing public health issue, and we are pleased by the increasing efforts in South Africa to improve awareness, preparedness and access to resources that support those at risk for anaphylaxis,” said Mylan CEO Heather Bresch. “Raising awareness and broadening education about the risk of food allergies is a critical mission for Mylan.”
Many people are unaware that a food allergy can cause a potentially life-threatening reaction. And even those with food allergies may not know that mild allergic reactions may be followed by a severe reaction after a second exposure to the same allergen.
Life happens, and those at risk of anaphylaxis need to be prepared, which means 1) avoiding known allergens; 2) knowing what symptoms to look for; 3) using an auto-injector should anaphylaxis occur and 4) seeking immediate emergency medical assistance.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com
1. About Anaphylaxis (https://www.anaphylaxis101.com/About-Anaphylaxis.aspx
2. Allergies and Anaphylaxis (http://www.webmd.com/allergies/guide/anaphylaxis#2
3. Food Allergy – A Rising Global Health Problem – World Allergy Week 2013 (http://www.worldallergy.org/UserFiles/file/WorldAllergyWeek2013final.pdf
4. Lieberman P, Camargo CA, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol